Latest Breaking News On - Patients with ph positive all - Page 1 : comparemela.com

Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.

United statesElias jabbourCourtney flahertyUniversity of texas md anderson cancer centerDivision of cancer medicineDepartment of leukemiaLive on airCancer medicineCancer centerOnclive on airApple podcastsGoogle podcastsAmazon musicFda approval of ponatinibPatients with ph positive allPhallcon trial